2016 Hematological Malignancies
GHSG HD18 trial for advanced stages: PFS Arm A
0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0
3-year PFS 8x BEACOPP, PET+ 91.4% 8x R-BEACOPP, PET+ 93.0%
PFS
8x BEACOPP, PET+
8x R-BEACOPP, PET+
0
12
24
36
48
Time [months]
219 BEACOPP 220 R-BEACOPP Pts. at Risk
204 200
162 162
87 81
33 15
Made with FlippingBook